Gainers Vistagen Therapeutics, Inc. (NASDAQ: VTGN) shares jumped 747.6% to $14.24 after the company announced its Phase 3 PALISADE-2 trial evaluating the efficacy, safety, and tolerability of fasedienol met the primary and secondary endpoints.
Curis (NASDAQ:CRIS – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a report issued on Friday, Benzinga reports. They currently have a $6.00 price target on the biotechnology company’s stock. Separately, StockNews.com cut shares of Curis from a “buy” rating to a “hold” rating in a research note […]
Curis, Inc. (NASDAQ:CRIS – Get Free Report) saw a large drop in short interest in July. As of July 15th, there was short interest totalling 1,580,000 shares, a drop of 8.1% from the June 30th total of 1,720,000 shares. Based on an average trading volume of 298,100 shares, the days-to-cover ratio is currently 5.3 days. […]
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study
Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib
Strong balance.